Form 4: Alumis Chief Business & Strategy Officer Granted Significant Equity Awards

Alumis Inc.'s Chief Business & Strategy Officer, Roy C. Hardiman, was granted 28,000 restricted stock units and 111,950 stock options, alongside an acquisition of 3,000 shares via the employee stock purchase plan.

Summary

• Roy C. Hardiman, Chief Business & Strategy Officer of Alumis Inc. (ALMS), received new equity awards.
• On July 29, 2025, Hardiman was granted 28,000 shares of common stock as Restricted Stock Units (RSUs) with a price of $0.
• These RSUs will vest 25% on August 1, 2026, with the remainder vesting in equal quarterly installments over the subsequent 12 quarters, contingent on continuous service.
• Additionally, on July 29, 2025, Hardiman was granted 111,950 stock options with an exercise price of $3.95 and a price of $0.
• These stock options will vest 25% on July 29, 2026, with the remainder vesting in equal monthly installments over the subsequent 36 months, contingent on continuous service, and expire on July 28, 2035.
• Hardiman's direct beneficial ownership of common stock following these transactions is 206,401 shares, which includes 3,000 shares acquired on May 20, 2025, under the Issuer's 2024 Employee Stock Purchase Plan.
• An additional 6,417 shares are indirectly beneficially owned by his daughter.

Sentiment

Score: 7

Explanation: The filing indicates a standard executive compensation event with significant equity grants, which is generally positive for executive retention and alignment with shareholder interests. No negative information is present.

Positives

• Significant equity grants to a key executive, Roy C. Hardiman, aligning his interests with long-term shareholder value.
• The grants include 28,000 Restricted Stock Units (RSUs) and 111,950 stock options, indicating confidence in the executive's continued contribution.
• Inclusion of shares acquired through the Employee Stock Purchase Plan (ESPP) suggests broader employee participation and investment in the company.

Risks

• Vesting of RSUs and stock options is subject to the Reporting Person's Continuous Service, meaning forfeiture if employment ceases before vesting dates.

Future Outlook

The filing details future vesting schedules for equity awards, indicating a long-term retention strategy for a key executive, contingent on continuous service through August 2026 and beyond for RSUs, and July 2026 and beyond for stock options.

Industry Context

This filing represents a routine executive compensation disclosure within the biotechnology or pharmaceutical industry, where equity grants are a standard component of executive incentive and retention programs. Such grants are common for Chief Business & Strategy Officers, reflecting their role in long-term strategic growth and partnerships.

Related Party Transactions

• 6,417 shares of common stock are indirectly beneficially owned by the Reporting Person's daughter, residing in his primary residence.

Stakeholder Impact

• Shareholders: The equity grants align the Chief Business & Strategy Officer's interests with long-term shareholder value, potentially encouraging strategic decisions that benefit the company's stock performance.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) indicates a broader program that allows employees to acquire company stock, fostering a sense of ownership.

Next Steps

• Continued vesting of 28,000 Restricted Stock Units (RSUs) with 25% vesting on August 1, 2026, and remaining shares vesting quarterly over the following 12 quarters.
• Continued vesting of 111,950 stock options with 25% vesting on July 29, 2026, and remaining shares vesting monthly over the following 36 months.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation grants to a key executive. While these grants align executive incentives with long-term company performance, they do not provide new fundamental information about the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. It's a standard disclosure of an expected compensation event.

Keywords

Alumis Inc., ALMS, SEC Form 4, Insider Trading, Equity Grant, Restricted Stock Units, RSU, Stock Options, Employee Stock Purchase Plan, ESPP, Executive Compensation, Roy C. Hardiman, Chief Business & Strategy Officer